CXCL12 and breast carcinoma: Since dimeric PKM2 is known to drive the glycolytic metabolism of glucose and accumulation of metabolites in glycolysis and the pentose phosphate pathway, our signaling data provide one potential mechanism for CXCL12-stimulated shifts in the metabolism of breast cancer cells.